Isaac Sangeetha, Pasha Mohammed Afraz, Isaac Shalom, Kyei-Nimako Evans, Lal Amos
Internal Medicine, North Alabama Medical Center, Florence, USA.
Critical Care Medicine, Christian Medical College, Vellore, IND.
Cureus. 2023 Mar 1;15(3):e35660. doi: 10.7759/cureus.35660. eCollection 2023 Mar.
Acute respiratory distress syndrome (ARDS) and pulmonary fibrosis (PF) are increasingly identified as complications of coronavirus disease 2019 (COVID-19) infection, the latter being managed with tapering dose glucocorticoids. Studies have shown improved outcomes with steroid use in this subset of patients; however, the use of high doses of steroids predisposes these patients to develop various complications such as opportunistic infections. The incidence of pulmonary cryptococcosis (PC) in patients with post-COVID-19 PF is not known. Here, we discuss a middle-aged male, with no pulmonary comorbidities, who developed PC secondary to the immunocompromised state from high-dose steroid use for the management of post-COVID-19 PF.
急性呼吸窘迫综合征(ARDS)和肺纤维化(PF)越来越多地被认为是2019冠状病毒病(COVID-19)感染的并发症,后者采用逐渐减量的糖皮质激素进行治疗。研究表明,在这部分患者中使用类固醇可改善预后;然而,使用高剂量类固醇会使这些患者易发生各种并发症,如机会性感染。COVID-19后PF患者中肺隐球菌病(PC)的发病率尚不清楚。在此,我们讨论一名中年男性,他没有肺部合并症,因使用高剂量类固醇治疗COVID-19后PF导致免疫功能低下状态而继发PC。